Yuan Ma | Biochemistry | Best Researcher Award

Posted on by Best Achievements

Dr. Yuan Ma | Biochemistry | Best Researcher Award

Dr. Yuan Ma, The Chinese University of Hong Kong ,China.

🔬 Dr. MA Yuan (Ph.D.) is a distinguished researcher in nucleic acid-based drug discovery and aptamer-based translational medicine. Currently a Research Assistant Professor at Hong Kong Baptist University, he has contributed extensively to targeted cancer therapies and precision medicine. With 35+ publications, multiple patents, and high-impact grants, his work advances innovative drug development. He also mentors Ph.D. and Master’s students, shaping the future of pharmaceutical sciences. His groundbreaking research continues to transform therapeutic strategies in oncology and molecular medicine. 🏆🔍

🌟 Professional Profile

🎓 Early Academic Pursuits

MA Yuan’s academic journey began at the School of Pharmaceutical Sciences, Peking University, where he earned a Bachelor of Science (2009-2013), specializing in organic chemistry, pharmacology, and pharmaceutical analysis. He continued his education at the Stake Key Laboratory of Natural and Biomimetic Drugs, Peking University, completing a Master of Science (2013-2015) with a focus on DNA synthesis, advanced medicinal chemistry, and tumor pharmacology. His Ph.D. (2015-2019) at the same institution delved into nucleic acid chemistry, advanced organic chemistry, and natural pharmaceutical chemistry, culminating in a thesis on the properties, biological activity, and mechanism of novel nucleoside (acid) lipid delivery of single-stranded oligonucleotides under the mentorship of Prof. Zhenjun Yang.

💼 Professional Endeavors

Dr. MA Yuan’s professional career spans prestigious institutions. Since 2022, he has been a Research Assistant Professor at the Institute for Precision Medicine and Innovative Drug, Hong Kong Baptist University, leading aptamer-based translational research and drug discovery. Previously, he was a Postdoctoral Research Fellow (2020-2022) at the same institution and an Associate Research Fellow (2019-2020) at Mengchao Hepatobiliary Hospital of Fujian Medical University, where he contributed to nucleic acid-based diagnosis and treatment of primary liver cancer.

🔬 Contributions and Research Focus On Biochemistry 

Dr. MA Yuan’s research primarily focuses on aptamer-based drug discovery, nucleic acid chemistry, and translational medicine. His expertise spans nucleic acid-based therapies, precision medicine, and advanced pharmaceutical formulations. He has supervised multiple postgraduate students, contributing to groundbreaking studies in triple-negative breast cancer, ovarian cancer therapy, and osteogenesis imperfecta.

🌍 Impact and Influence

Through his research, Dr. MA Yuan has secured major research grants exceeding HK$ 51 million from institutions such as the Research Grants Council and the National Natural Science Foundation of China. His work has contributed significantly to novel drug discoveries and advancements in precision medicine. He also holds three patents for innovations in nucleic acid drug delivery and targeted cancer treatments.

🏆 Awards and Honors

Dr. MA Yuan has received several prestigious awards and recognitions, including Orphan Drug and Rare Pediatric Disease Designations from the FDA for his contributions to osteogenesis imperfecta and gastric cancer treatments.

📚Academic Citations

Dr. MA Yuan has authored 35 peer-reviewed publications in esteemed journals, furthering knowledge in nucleic acid chemistry, aptamer-based therapies, and pharmacology. His work has been widely cited, reflecting its impact on biomedical research and pharmaceutical sciences.

  • Machine learning-powered, high-affinity modification strategies for aptamers
    Journal: Acta Materia Medica
    Year: 2025
    📚🤖

  • Peptide Aptamer–Paclitaxel Conjugates for Tumor Targeted Therapy
    Journal: Pharmaceutics
    Year: 2024
    💊🎯

  • Developing Stapled Aptamers with a Constrained Conformation for Osteogenesis Imperfect Therapeutics
    Journal: Journal of Medicinal Chemistry
    Year: 2024
    🧬💉

  • Targeting osteoblastic 11β-HSD1 to combat high-fat diet-induced bone loss and obesity
    Journal: Nature Communications
    Year: 2024
    🍔🦴

  • Aptamer Functionalized Hypoxia-potentiating Agent and Hypoxia-inducible Factor Inhibitor Combined with Hypoxia-activated Prodrug for Enhanced Tumor Therapy
    Journal: Cancer Letters
    Year: 2024
    Citations: Not Available
    🧬🦠

  • Advancing targeted combination chemotherapy in triple negative breast cancer: nucleolin aptamer-mediated controlled drug release
    Journal: Journal of Translational Medicine
    Year: 2024
    🎗️💪

  • Sclerostin inhibition in rare bone diseases
    Journal: Journal of Orthopaedic Translation
    Year: 2024
    🦵🦴

  • Small RNAs in Cancer Therapy
    Book Chapter: Interdisciplinary Cancer Research
    Year: 2024
    Citations: Not Available
    📖🧬

  • Aptamer AS411 interacts with the KRAS promoter/hnRNP A1 complex and shows increased potency against drug-resistant lung cancer
    Journal: RSC Medicinal Chemistry
    Year: 2024
    🚬💪

  • Design and synthesis of nucleotidyl lipids and their application in the targeted delivery of siG12D for pancreatic cancer therapy
    Journal: Biomedicine and Pharmacotherapy
    Year: 2024
    🍍🔬

  • Unique quinoline orientations shape the modified aptamer to sclerostin for enhanced binding affinity and bone anabolic potential
    Journal: Molecular Therapy – Nucleic Acids
    Year: 2024
    🦴🔬

  • The Modification Strategies for Enhancing the Metabolic Stabilities and Pharmacokinetics of Aptamer Drug Candidates
    Book Chapter: Drug Metabolism and Pharmacokinetics
    Year: 2024
    💊🧬

  • Intracellular sclerostin plays a vital role in tumor progression and metastasis in triple-negative breast cancer
    Journal: Cancer Research
    Year: 2024
    🧠🔬

  • A bimolecular modification strategy for developing long-lasting bone anabolic aptamer
    Journal: Molecular Therapy – Nucleic Acids
    Year: 2023
    🦴✨

Rui Wang | Molecular Biology | Best Researcher Award

Posted on by Best Achievements

Mrs.  Rui Wang | Molecular Biology | Best Researcher Award

Mrs. Rui Wang, Beijing Children’s Hospital, China.

Rui Wang is a distinguished researcher specializing in environmental science and microbiology. With a Ph.D. in Environmental Engineering from the Chinese Academy of Sciences and a Master’s degree in Earth and Environmental Science from the University of Paul Cezanne, France, his academic journey is marked by excellence. His research focuses on antibiotics and heavy metals residue analysis, gut microbiota’s role in obesity, and antibiotic resistance genes. Dr. Wang has made significant contributions through projects addressing global challenges and has authored numerous impactful publications. His expertise in advanced analytical techniques further reinforces his role as a leader in his field.

Author Profile:

Scopus Profile

Summary of Suitability for Best Researcher Award:

Dr. Rui Wang  is highly suited for the Best Researcher Award due to his extensive and impactful research in environmental engineering, microbiology, and antibiotic resistance. His work, spanning multiple international projects, focuses on antibiotic and heavy metal residues in complex matrices and their effects on gut microbiota, with particular attention to obesity and antibiotic resistance. Rui’s diverse research experience includes leading projects funded by the National Natural Science Foundation of China and conducting influential studies on anaerobic digestion, wastewater treatment, and microbial community dynamics.

🎓 Education Background:

Dr. Rui Wang possesses an impressive educational background that forms the foundation of his research expertise. He earned his Ph.D. in Environmental Engineering from the prestigious Chinese Academy of Sciences, where his dissertation explored the effects of tetracyclines, copper, and their resistance genes on swine manure anaerobic digestion. Prior to this, he completed a Master’s degree in Earth and Environmental Science at the University of Paul Cezanne, France, focusing on arsenic uptake around rice roots in contaminated soils. Rui Wang began his academic journey with a Bachelor’s degree in Water Supply and Sewerage Engineering from Hebei University of Engineering, China.

💼 Professional Experience:

Dr. Rui Wang has extensive professional experience in environmental sciences and analytical chemistry. He served as a Postdoctoral Fellow in Biology at the Research Center for Eco-Environmental Sciences, Chinese Academy of Sciences, from 2015 to 2017. During this time, he conducted groundbreaking research on antibiotic resistance genes and their environmental impacts. Dr. Wang has also contributed significantly to water quality analysis through his role in projects such as the China-Sri Lanka Joint Center for Water Technology Research. Additionally, his expertise in advanced instrumentation, including HPLC-MS, ICP-MS, and GC-MS, has enabled him to develop innovative methods for analyzing complex environmental matrices.

🌍Research Contributions:

Dr. Rui Wang has made substantial contributions to environmental science, microbiology, and public health. His research addresses critical issues such as the analysis of antibiotic and heavy metal residues in complex matrices, the role of gut microbiota in obesity, and antibiotic resistance genes. Dr. Wang has led several impactful projects, including studies on the fate of antibiotics in swine manure anaerobic digestion and the effects of acetic acid on obesity-related intestinal microbes. His work on monitoring antibiotics in livestock and wastewater treatment systems has provided valuable insights into environmental health. With numerous publications, he continues to drive innovation in these fields.

🥇Award and Recognition

Dr. Rui Wang is a highly accomplished researcher whose work in environmental science and microbiology has made significant contributions to global health and environmental sustainability. Holding a Ph.D. in Environmental Engineering from the Chinese Academy of Sciences, his research focuses on critical areas such as antibiotics and heavy metals residue analysis, the gut microbiota’s role in obesity, and antibiotic resistance genes. With numerous impactful publications and international conference presentations, Dr. Wang’s expertise in advanced analytical techniques further solidifies his leadership in the field. His innovative approach and dedication to addressing pressing issues make him a deserving candidate for the Best Researcher Award.

Conclusion:

Dr. Rui Wang’s extensive academic background and pioneering research make him an ideal candidate for the Best Researcher Award. His work on antibiotics, heavy metals, and the gut microbiota’s role in obesity addresses pressing global health and environmental challenges. Dr. Wang’s leadership in innovative projects, combined with his proficiency in advanced analytical techniques, showcases his exceptional contributions to environmental science and microbiology. His numerous publications, international conference presentations, and commitment to advancing knowledge in his field demonstrate his lasting impact, making him a highly deserving candidate for this prestigious recognition.

📚Publication Top Notes

Simulating the multi-media fate of perfluorooctane sulfonate (PFOS) and its precursors in the Bohai coastal region of China

Year: 2024

Publication: Science of the Total Environment

🌊🔬

Vitamin D alleviates HFD-induced hepatic fibrosis by inhibiting DNMT1 to affect the TGFβ1/Smad3 pathway

Year: 2024

Publication: iScience

💊🧬

Generation of RAB4A homozygous knockout induced pluripotent stem cell (iPSC) line

Year: 2024

Publication: Stem Cell Research

🧫🔬

Emission estimation and health risk evaluation of aquaculture drugs commonly used in China

Year: 2024

Publication: Science of the Total Environment

Citations: 1

🐟💡

Imbalance of early-life vitamin D intake targets ROS-mediated crosstalk between mitochondrial dysfunction and differentiation potential of MSCs associated with later obesity

Year: 2024

Publication: Stem Cell Research and Therapy

Citations: 1

🧬💪

Interactions and Conflicts between Urbanization and Greenness: A Case Study from Nanjing, China

Year: 2024

Publication: Remote Sensing

🏙️🌳

Decreased vitamin D bio-availability with altered DNA methylation of its metabolism genes in association with the metabolic disorders among school-aged children with degree I, II, and III obesity

Year: 2024

Publication: Journal of Nutritional Biochemistry

🧬🍽️

Simulating behavior of perfluorooctane sulfonate (PFOS) in the mainstream of a river system with sluice regulations

Year: 2024

Publication: Chemosphere

Citations: 1

🌊⚙️

Paternal preconceptional supplementation of n-3 polyunsaturated fatty acids alleviates offspring nonalcoholic fatty liver disease in high-fat diet-induced obese mice

Year: 2024

Publication: Food Frontiers🍔💊

Biomagnification and health risks of perfluoroalkyl acids (PFAAs) in seafood from the Yangtze river estuary of China

Year: 2024

Publication: Environmental Pollution

🦑💧